PT -期刊文章盟- l . Lacomblez AU - g . Bensimon AU - p . n .李盟- p . Guillet AU - l·鲍威AU - s Durrleman AU - j . c . Delumeau AU - v .专职阿訇TI -确认dose-ranging研究利鲁唑ALS援助- 10.1212 / WNL.47.6_Suppl_4.242S DP - 1996年12月01 TA -神经病学PG - 242年代——250年代VI - 47 IP - 6 5 4 4099 - http://n.neuro首页logy.org/content/47/6_Suppl_4/242S.short 4100 - //www.ez-admanager.com/content/47/6_Suppl_4/242S.full所以Neurology1996 12月01;47 AB - ALS是一个进步的运动神经元疾病,没有有效的治疗方法。专业药物利鲁唑(100毫克/天)已被证明会降低死亡率和ALS患者的肌肉退化。确认和扩展利鲁唑的治疗效果,我们进行了双盲、安慰剂对照、多中心、国际dose-ranging(100, 200毫克/天),959年的分层研究肌萎缩性侧索硬化症门诊治疗长达18个月。主要功效标准是生存和治疗的效果进行了分析(Wilcoxon和日志等级测试)和前调整后预后因素(Cox模型)。次要疗效标准是通过改变疾病进展评估功能的措施。Tracheostomy-free存活率是:50.4%(安慰剂),55.3%(50毫克利鲁唑)(p = 0.23, Wilcoxon测试;生存率较p = 0.25), 56.8%(100毫克利鲁唑)(p = 0.05, Wilcoxon测试;生存率较p = 0.076), 57.8%(200毫克利鲁唑)(p = 0.061, Wilcoxon测试;生存率较,p = 0.075)。 At the end of the 18-month study, there was a significant dose-related decrease in risk of death or tracheostomy (p = 0.04). Adjustment for baseline prognostic factors showed a 35% decreased risk of death with the 100-mg dose compared with placebo (p = 0.002). No significant treatment effects were detected for the functional assessments. The most frequent dose-related adverse events included nausea, asthenia, and elevated liver enzyme levels. This study confirms the therapeutic effect of riluzole in a large representative ALS sample, over an 18-month period. Riluzole is well tolerated and decreases the risk of death or tracheostomy in ALS patients. NEUROLOGY 1996;47(Suppl 4): S242-S250

map